Why Pacific Biosciences of California, Inc. (PACB) stock fell 6.7% on Wednesday, November 11, 2026
Pacific Biosciences of California, Inc. (PACB) closed at $2.09, down 6.70% on Wednesday, November 11, 2026, on volume of 10,655,192 shares (0.9× its 3-month average); market value about $600.0M, according to Nexqual market data (nexqual.com/moves/2026-11-11/PACB).
What happened: primary sources
Events Nexqual found for PACB on Wednesday, November 11, 2026 or the trading day before (November 10, 2026), each linked to its primary source:
- Nov 10, 2026: SEC 8-K: Entered a material agreement source
Quoted from the filing: “On November 10, 2026, Pacific Biosciences of California, Inc. (the "Company") entered into a Sales Agreement (the "Sales Agreement") with Allen & Company LLC ("Allen") to sell shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), having aggregate sales proceeds of up to $100,000,000 (the "Shares") , from time to time, through an "at-the-market" equity offering program under which Allen will act as sales agent. Under the Sales Agreement, the Company will set the parameters for the…”
These are listed as context. A filing or rating change on the same day is not proof that it caused the move; read the source.
More on PACB
PACB stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. Other big moves that day: November 11, 2026.
Sources: SEC EDGAR, Nexqual Earnings Flash, analyst rating changes, Nexqual market data. Built November 18, 2026 at 20:53 UTC. Not investment advice.
Data source: Nexqual. Last updated: November 18, 2026 at 20:53 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt